Aiming Yu, Ph.D.

Professor
2130 Oak Park Research Building
2700 Stockton Blvd.
Sacramento, CA 96817
Ph: 916-734-1566
Fax: 916-734-4418
e-mail

Research Interests

Dr. Yu’s research interests include drug metabolism, pharmacokinetics, noncoding RNAs, anticancer pharmacology and experimental therapeutics. The ultimate goal of his research is to translate noncoding RNAs to new therapies. Current efforts in his laboratory are directed to the investigation of (a) the mechanistic actions of microRNAs in the regulation of cancer cellular processes including drug/xenobiotic disposition and tumor progression and metastasis, (b) novel RNA bioengineering technologies, and (c) recombinant RNAs for basic research and drug development.

Dr. Yu also directs the PK/PD Bioanalytical Core Facility that provides services in support of the clinical and preclinical drug development programs, and the Molecular Pharmacology Shared Resources that supports high-quality collection, processing and analysis of clinical specimens and conducts preclinical modeling and evaluation of novel anticancer agents or combination.

Graduate Group Affiliations

See other publications on: PubMed | Google Scholar

Articles:

  1. Deng L, Petrek H, Tu MJ, Batra N, Yu AX, Yu AM. Bioengineered miR-124-3p prodrug selectively alters the proteome of human carcinoma cells to control multiple cellular components and lung metastasis in vivo. Acta Pharmaceutica Sinica B. (in press).
  2. Liu C, Armstrong C, Ning S, Yang J, Lou W, Lombard A, Zhao J, Wu CY, Yu AM, Evans CP, Tepper C, Li PK, Gao AC. ARVib suppresses growth of advanced prostate cancer via inhibition of androgen receptor signaling. Oncogene. (Online ahead of print) (2021).
  3. Petrek H, Ho PY, Batra N, Tu MJ, Zhang QY, Qiu JX, Yu AM. Single bioengineered ncRNA molecule for dual-targeting toward the control of non-small cell lung cancer patient-derived xenograft tumor growth. Biochem Pharmacol. 189:114392 (2021).
  4. Choi YH, Zhang C, Liu Z, Tu MJ, Yu AX, Yu AM. A novel integrated pharmacokinetic-pharmacodynamic model to assess combination therapy and determine in vivo J. Pharmacol. Exp. Ther. 377(3):305-315 (2021). (Front Cover of the June 2021 Issue).
  5. Li PC, Tu MJ, Ho PY, Batra N, Tran MML, Qiu JX, Wun T, Lara PN, Hu X, Yu AX, Yu AM. In vivo fermentation production of humanized noncoding RNAs for functional and experimental therapeutic studies. Theranostics. 11(10):4858-4871 (2021).
  6. Jilek JL, Tu MJ, Zhang C, Yu AM. Pharmacokinetic and pharmacodynamic factors contribute to synergism between let-7c-5p and 5-fluorouracil in inhibiting hepatocellular carcinoma cell viability. Drug Metab Dispos. 48(12):1257-1263 (2020).
  7. Tu MJ, Duan Z, Liu Z, Zhang C, Bold RJ, Gonzalez FJ, Kim EJ, Yu AM. MicroRNA-1291-5p sensitizes pancreatic carcinoma cells to arginine deprivation and chemotherapy through the regulation of arginolysis and glycolysis. Mol Pharmacol. 98(6):686-694 (2020).
  8. Yu AM, Choi YH, Tu MJ. RNA drugs and RNA targets for small molecules: Principles, progresses, and challenges. Pharmacol Rev. 72(4):829-861 (2020).
  9. Umeh-Garcia M, Simion C, Ho PY, Batra N, Berg A, Carraway III K, Yu AM, Sweeney C. A novelbioengineered microRNA-127 prodrug suppresses the growth and metastatic potential of triple negative breast cancer cells. Cancer Res. 80(3):418-429 (2020).
  10. Yi WR, Tu MJ, Liu Z, Zhang C, Batra N, Yu AX, Yu AM. Bioengineered miR-328-3p modulates GLUT1-mediated glucose uptake and metabolism to exert synergistic antiproliferative effects with chemotherapeutics. Acta Pharmaceutica Sinica B. 10(1):159-170 (2020).
  11. Petrek H, Batra N, Ho PY, Tu MJ, Yu AM. Bioengineering of a single long non-coding RNA molecule that carries multiple small RNAs. Appl Microbiol Biotechnol. 103(15):6107-6117 (2019).
  12. Xu J, Sun J, Ho PY, Ma W, Luo Z, Xie W, Yu AM, Li S. Creatine Based Polymer for Codelivery of Bioengineered MicroRNA and Chemodrugs against Breast Cancer Lung Metastasis, Biomaterials. 210:25-40 (2019).
  13. Jilek JL, Zhang QY, Tu MJ, Ho PY, Duan Z, Yu AM. Bioengineered Let-7c Loaded Lipopolyplex Inhibits Hepatocellular Carcinoma and Improves Overall Survival with Minimal Immunogenicity. Mol. Ther. Nucleic Acids. 14:498-508 (2019).
  14. Yu AM, Jian C, Yu AH, Tu MJ. RNA Therapy: Are we using the right molecules? Pharmacol Ther. 196:91-104 (2019).
  15. Tu MJ, Ho PY, Zhang QY, Jian C, Qiu JX, Kim EJ, Bold RJ, Gonzalez FJ, Bi H, Yu AM. Bioengineered miRNA-1291 prodrug therapy in pancreatic cancer cells and patient-derived xenograft mouse models. Cancer Lett. 442:82-90 (2019).
  16. Ho PH, Duan Z, Batra N, Jilek JL, Tu MJ, Qiu JX, H Z, Wun T, Lara PN, DeVere White RW, Chen HW, Yu AM. Noncoding RNA carrier (nCAR) enables high-success-rate, high-yield production of target RNAi agents in bacterial fermentation to modulate human cell transcriptome. J. Pharmacol. Exp. Ther. 365(3):494-506 (2018).
  17. Jilek JL, Tian Y and Yu AM. Effects of MicroRNA-34a on the Pharmacokinetics of Cytochrome P450 Probe Drugs in Mice. Drug Metab Dispos. 45(5):512-522 (2017).
  18. Yu AM, Tian Y, Tu MJ, Ho PY, Jilek JL. MicroRNA pharmacoepigenetics: Posttranscriptional regulation mechanisms behind variable drug disposition and strategy to develop more effective therapy. Drug Metab Dispos. 44(3):308-319 (2016).
  19. Wang WP, Ho PY, Li MM, Chen QX, Addepalli B, Tu MJ, Limbach PA, Li MM, Wu WJ, Jilek JL, Qiu JX, Zhang HJ, Li T, Wun T, DeVere White R, Lam KS, Yu AM. Bioengineering novel chimeric microRNA-34a for prodrug cancer therapy: High-yield expression and purification, and structural and functional characterization. J. Pharmacol. Exp. Ther. 354(2):131-141 (2015).
  20. Chen QX, Wang WP, Zeng S, Uroyama S, Yu AM. A general approach to high-yield biosynthesis of chimeric RNAs bearing various types of functional small RNAs for broad applications. Nucleic Acids Res, 43(7):3857-3869 (2015).

Patents:

  1. US Patent No. 11,041,201, Issued on June 22, 2021.
  2. European Patent No. 3150980, Granted on May 20, 2020.
  3. US Patent No. 10,619,156, Issued on April 14, 2020.

Graduate Courses

  • PTX201 Principles of Pharmacology and Toxicology I
  • VMB253 Drug Metabolism and Disposition
  • BCB299 Research
  • PTX299 Research